Ecosyste.ms: Awesome
An open API service indexing awesome lists of open source software.
https://github.com/wlandau/rpharma2020
Slides and source code for a talk about targets at R/Pharma 2020.
https://github.com/wlandau/rpharma2020
data-science high-performance-computing make pipeline r reproducibility reproducible-research rstats statistics targets workflow
Last synced: 25 days ago
JSON representation
Slides and source code for a talk about targets at R/Pharma 2020.
- Host: GitHub
- URL: https://github.com/wlandau/rpharma2020
- Owner: wlandau
- Created: 2020-08-19T18:34:15.000Z (over 4 years ago)
- Default Branch: main
- Last Pushed: 2020-10-15T13:20:10.000Z (over 4 years ago)
- Last Synced: 2024-11-05T04:42:17.882Z (2 months ago)
- Topics: data-science, high-performance-computing, make, pipeline, r, reproducibility, reproducible-research, rstats, statistics, targets, workflow
- Language: HTML
- Homepage: https://wlandau.github.io/rpharma2020
- Size: 2.47 MB
- Stars: 1
- Watchers: 3
- Forks: 0
- Open Issues: 0
-
Metadata Files:
- Readme: README.md
Awesome Lists containing this project
README
# Reproducible computation at scale in R with targets
Data science can be slow. A single round of statistical computation can take several minutes, hours, or even days to complete. The targets R package keeps results up to date and reproducible while minimizing the number of expensive tasks that actually run. The targets package learns how your pipeline fits together, skips costly runtime for steps that are already up to date, runs the rest with optional implicit parallel computing, abstracts files as R objects, and shows tangible evidence that the output matches the underlying code and data. In other words, the package saves time while increasing our ability to trust the conclusions of the research. In addition, it surpasses the most burdensome permanent limitations of its predecessor, drake, to achieve greater efficiency and provide a safer, smoother, friendlier user experience. This talk debuts targets with an example COVID-19 clinical trial simulation study.